<?xml version="1.0" encoding="UTF-8"?>
<results title="test_trace">
 <result pre="in the market. We studied the comparative safety, effectiveness, and" exact="treatment" post="costs of the two first generation direct-acting antiviral agents"/>
 <result pre="the drug of choice between these two seemingly equally Hepatitis-C" exact="treatment" post="options. Methods We randomly assigned 50 patients in an"/>
 <result pre="and ribavirin, stratified by the presence of cirrhosis and prior" exact="treatment" post="experience. Tolerability was assessed at each visit and reasons"/>
 <result pre="was assessed at each visit and reasons for discontinuation of" exact="treatment" post="and severity of adverse events due to PI treatment"/>
 <result pre="of treatment and severity of adverse events due to PI" exact="treatment" post="were adjudicated using a blinded adjudication committee. The primary"/>
 <result pre="response rates and cost-per cure achieved. Results Higher rates of" exact="treatment" post="discontinuations and/or severe DAA associated adverse events were seen"/>
 <result pre="a significantly higher rate of severe adverse events leading to" exact="treatment" post="discontinuations, hospitalizations or severe anemia and a substantially higher"/>
 <result pre="the study involved veterans and was conducted in a federal" exact="treatment" post="facility, there are legal restrictions prohibiting us from making"/>
 <result pre="the criteria for access to confidential data. Interested researchers may" exact="contact" post="the corresponding author of the manuscript for further information"/>
 <result pre="have chronic HCV, which is more than double the estimated" exact="prevalence" post="of HCV in the general US population.[5] Untreated HCV"/>
 <result pre="to other adverse reactions, thereby greatly increasing the risk of" exact="treatment" post="discontinuations and dose reductions.[14] The first generation nonstructural 3/4A"/>
 <result pre="States Food and Drug Administration (FDA) in 2011 for the" exact="treatment" post="of HCV genotype 1 (GT1) infection.[15, 16] When compared"/>
 <result pre="16] When compared to SVR rates obtained with the standard" exact="treatment" post="regimen of Peg-IFN with RBV (38–44%) in clinical trials,"/>
 <result pre="for some clinicians might have been influenced by its shorter" exact="treatment" post="duration (12 weeks) vs. boceprevir (24/44 weeks). Alternatively, as"/>
 <result pre="important role in facilitating decisions in selection between seemingly comparable" exact="treatment" post="choices. The primary objective of this RCT was to"/>
 <result pre="was to compare tolerability of boceprevir vs. telaprevir in HCV" exact="treatment" post="in treatment naïve and treatment experienced veterans. The secondary"/>
 <result pre="compare tolerability of boceprevir vs. telaprevir in HCV treatment in" exact="treatment" post="naïve and treatment experienced veterans. The secondary objectives were:"/>
 <result pre="boceprevir vs. telaprevir in HCV treatment in treatment naïve and" exact="treatment" post="experienced veterans. The secondary objectives were: a) to evaluate"/>
 <result pre="sequence was utilized to allocate subjects to one of two" exact="treatment" post="groups, boceprevir or telaprevir. Allocation was concealed using serially"/>
 <result pre="opaque, sealed envelopes. Study subjects were stratified based on prior" exact="treatment" post="experience and presence or absence of cirrhosis. There was"/>
 <result pre="and MGS) who determined if adverse events (AE) leading to" exact="treatment" post="discontinuation were related to the DAAs being studied. The"/>
 <result pre="the DAAs being studied. The committee also made decisions of" exact="treatment" post="cessation due to virologic failure. Reporting of this RCT"/>
 <result pre="Eligible patients were adult veterans (≥18 years) with HCV GT1" exact="infection" post="and evidence of chronic hepatitis. The presence of cirrhosis"/>
 <result pre="administered through regular clinical care without masking (open label). All" exact="treatment" post="doses were provided according to the standard Food and"/>
 <result pre="and Peg-IFN/RBV. Dosing for boceprevir (according to product labeling): HCV" exact="treatment" post="naïve patients and relapsers received boceprevir for 24 to"/>
 <result pre="48 weeks. Dosing for telaprevir (according to product labeling): HCV" exact="treatment" post="naïve patients/relapsers received telaprevir for 12 weeks and Peg-IFN/RBV"/>
 <result pre="12 weeks and Peg-IFN/RBV for 24 or 48 weeks. Again," exact="treatment" post="duration was dependent on patient response after 4 weeks"/>
 <result pre="of this trial was tolerability of the DAAs. Data regarding" exact="treatment" post="tolerability and adverse events were assessed at study entry"/>
 <result pre="2 followed by every 4 weeks until the end of" exact="treatment" post="as per the product labeling. All AEs, the incidence"/>
 <result pre="of specific AEs, and severe adverse events (SAE) leading to" exact="treatment" post="discontinuation or hospitalization were documented and presented to the"/>
 <result pre="treated with Peg-IFN/RBV and out of these 12 (57%) were" exact="treatment" post="failures and nine (43%) were prior treatment responder-relapsers. Patient"/>
 <result pre="12 (57%) were treatment failures and nine (43%) were prior" exact="treatment" post="responder-relapsers. Patient characteristics are shown in Table 1. 10.1371/journal.pone.0163945.t001Table"/>
 <result pre="SD: Standard Deviation. Treatment tolerability and safety Higher rates of" exact="treatment" post="discontinuations and/or severe PI associated AEs were seen in"/>
 <result pre="5; 95% CI: 1.2, 20; p&amp;lt;0.01). Eight patients discontinued telaprevir" exact="treatment" post="early due to toxicity (mostly due to rashes); one"/>
 <result pre="≤8 g/dL). Of the two patients on boceprevir who stopped" exact="treatment" post="early, one experienced a severe rash and the other"/>
 <result pre="Four patients (3 on boceprevir and 1 on telaprevir) discontinued" exact="treatment" post="early due to adverse events felt most likely related"/>
 <result pre="most likely related to Peg-IFN/RBV. Two patients (one in each" exact="treatment" post="group) experienced mood disturbances while two patients on boceprevir"/>
 <result pre="25) P value Treatment-emergent AEs due to PI leading to" exact="treatment" post="discontinuation [n (%)]  • Toxicity* 2 (8) 8 (32)"/>
 <result pre="(8) 10 (40) &amp;lt;0.01 AEs due to Peg-IFN/RBV leading to" exact="treatment" post="discontinuation [n (%)]  • Mood disturbances 1 (4) 1"/>
 <result pre="RBV: Ribavirin. Based on the overall poor tolerability of the" exact="treatment" post="regimens, the investigators decided to stop the trial early."/>
 <result pre="which was associated with fewer side effects, or continue without" exact="treatment" post="until the VA formulary approved the second generation DAAs."/>
 <result pre="to telaprevir, 12 patients achieved SVR24 (48%). SVR24 rates by" exact="treatment" post="stratification are presented in Table 3. 10.1371/journal.pone.0163945.t003Table 3 SVR24"/>
 <result pre="presented in Table 3. 10.1371/journal.pone.0163945.t003Table 3 SVR24 rates based on" exact="treatment" post="exposure to boceprevir and telaprevir. Boceprevir (n = 25)"/>
 <result pre="had on average 13 outpatient visits related to their HCV" exact="treatment" post="vs. 9 outpatient visits for those in the telaprevir"/>
 <result pre="evaluation due to AE* $2,260.00 $11,330.00  • Drugs used for" exact="treatment" post="of AE (Epo+Fil) $12,541.00 $13,264.00  • Cost of adverse"/>
 <result pre="Cost of adverse events per study arm $14,801.00 $24,594.00 Total" exact="treatment" post="cost per SVR $44,329.25 $57,115.17 *Outpatient evaluation by nurse"/>
 <result pre="higher rate of severe adverse events (treatment toxicity) leading to" exact="treatment" post="discontinuations. Treatment efficacy rates were not significantly different between"/>
 <result pre="Treatment efficacy rates were not significantly different between the two" exact="treatment" post="groups, but both telaprevir and boceprevir showed substantially lower"/>
 <result pre="cure rates than observed in the registration trials. Cost of" exact="treatment" post="per cure was substantially higher for telaprevir when compared"/>
 <result pre="treatment. Given the lack of evidence-based guidelines concerning hepatitis C" exact="treatment" post="when these drugs were approved, clinicians preferred using telaprevir"/>
 <result pre="preferred using telaprevir based triple therapy, presumably given its shorter" exact="treatment" post="duration and a perceived better response rate since real-world"/>
 <result pre="treatment duration and a perceived better response rate since real-world" exact="treatment" post="experience reports were lacking.[19, 20] In contrast, boceprevir was"/>
 <result pre="formulary choice in VHA based on its competitive pricing. Both" exact="treatment" post="selection approaches should have been classified as preliminary as"/>
 <result pre="achieved, our study was underpowered to detect important differences in" exact="treatment" post="efficacy. However, despite a smaller sample size, a statistically"/>
 <result pre="significantly impact tolerance and thus SVR rates seen in real-life" exact="treatment" post="results. These drugs typically cost between $63,000 to $94,500"/>
 <result pre="typically cost between $63,000 to $94,500 for 8-12-week regimens.[30] When" exact="treatment" post="costs are high, comparative effectiveness data become important. While"/>
 <result pre="provide real-time, comparative effectiveness and resource use data. Particularly when" exact="treatment" post="costs are high as in the case of these"/>
 <result pre="of these newer antiviral combination regimens, even small differences in" exact="treatment" post="efficacy and/or adverse events leading to treatment discontinuation will"/>
 <result pre="small differences in treatment efficacy and/or adverse events leading to" exact="treatment" post="discontinuation will lead to significant differences in cost per"/>
 <result pre="aging population can be particularly useful in guiding hepatitis C" exact="treatment" post="choices. Based on our findings and the availability of"/>
 <result pre="availability of newer DAAs, we discontinued the initiation of new" exact="treatment" post="regiments with telaprevir. Real-time, point of care, pragmatic randomized"/>
 <result pre="care, pragmatic randomized controlled trials are necessary to make evidence-based" exact="treatment" post="selections when multiple effective treatments are available. Supporting Information"/>
 <result pre="World Health Organization (2014). Guidelines for the screening, care and" exact="treatment" post="of persons with hepatitis C infection. World Health Organization"/>
 <result pre="Available at: http://www.who.int/hiv/pub/hepatitis/hepatitis-c-guidelines/en/ 3ArmstrongGL, WasleyA, SimardEP, McQuillanGM, KuhnertWL, AlterMJ. The" exact="prevalence" post="of hepatitis C virus infection in the United States,"/>
 <result pre="SimardEP, McQuillanGM, KuhnertWL, AlterMJ. The prevalence of hepatitis C virus" exact="infection" post="in the United States, 1999 through 2002. Annals of"/>
 <result pre="JilesRB, DrobeniucJ, KlevensRM, WardJW, McQuillanGM, et al.Chronic hepatitis C virus" exact="infection" post="in the United States, National Health and Nutrition Examination"/>
 <result pre="10.7326/M13-1133 .24737271 5DominitzJA, BoykoEJ, KoepsellTD, HeagertyPJ, MaynardC, SporlederJL, et al.Elevated" exact="prevalence" post="of hepatitis C infection in users of United States"/>
 <result pre="KoepsellTD, HeagertyPJ, MaynardC, SporlederJL, et al.Elevated prevalence of hepatitis C" exact="infection" post="in users of United States veterans medical centers. Hepatology."/>
 <result pre="7SaitoI, MiyamuraT, OhbayashiA, HaradaH, KatayamaT, KikuchiS, et al.Hepatitis C virus" exact="infection" post="is associated with the development of hepatocellular carcinoma. Proceedings"/>
 <result pre="et al.Recommendations for the identification of chronic hepatitis C virus" exact="infection" post="among persons born during 1945–1965. MMWR Recomm Rep. 2012;61(RR-4):1–32."/>
 <result pre="al.Interferon alfa-2b alone or in combination with ribavirin as initial" exact="treatment" post="for chronic hepatitis C. Hepatitis Interventional Therapy Group. The"/>
 <result pre="weeks versus interferon alpha2b plus placebo for 48 weeks for" exact="treatment" post="of chronic infection with hepatitis C virus. International Hepatitis"/>
 <result pre="alpha2b plus placebo for 48 weeks for treatment of chronic" exact="infection" post="with hepatitis C virus. International Hepatitis Interventional Therapy Group"/>
 <result pre="KaleH, MullenKD, SarbahSA, SorescuL, McCulloughAJ. Surprisingly small effect of antiviral" exact="treatment" post="in patients with hepatitis C. Annals of internal medicine."/>
 <result pre="telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1" exact="infection" post="and cirrhosis. Gastroenterology. 2014;147(1):132–42 e4. 10.1053/j.gastro.2014.03.051 .24704719 20BonnetD, GuivarchM,"/>
 <result pre="RobertsMS, DunnMA. Cost-effectiveness and budget impact of hepatitis C virus" exact="treatment" post="with sofosbuvir and ledipasvir in the United States. Ann"/>
</results>
